Company
Headquarters: Lianyungang, China
Employees: 28,903
CN¥246.80 Billion
CNY as of Jan. 1, 2023
US$35.78 Billion
Company | Market Cap (USD) |
---|---|
![]() |
$461.85 B |
![]() |
$347.61 B |
![]() |
$287.63 B |
![]() |
$285.80 B |
![]() |
$281.30 B |
Company | Market Cap (USD) |
---|---|
![]() |
$495.37 B |
![]() |
$461.85 B |
![]() |
$347.61 B |
![]() |
$304.61 B |
![]() |
$287.63 B |
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Jiangsu Hengrui Medicine Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600276